What Is GLP-3?
A Next-Generation Triple-Agonist Approach Under Study in Weight Management and Metabolic Health
GLP-3 is the term used here to describe a next-generation approach that combines activity at three metabolic hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These signaling pathways are involved in appetite, glucose regulation, insulin response, energy intake, and energy expenditure.
It has attracted scientific and clinical interest because combining three receptor pathways may produce metabolic effects beyond targeting GLP-1 alone or GLP-1 and GIP together. Triple-receptor agonism is being studied for its effects on body weight, blood glucose regulation, and other measures of metabolic health.
GLP-3 is not a formal scientific name for a hormone or receptor. The term is being used here to describe this next-generation triple-receptor approach.
Have questions about peptide therapy? Call Advanced Mobile IV to speak with our team.
What Researchers Are Studying
-
Appetite and Weight Regulation
GLP-1 and GIP signaling influence metabolic responses to food intake, while glucagon receptor activity may contribute additional effects on energy balance. Researchers are studying whether combining these three pathways can produce substantial and sustained effects on body weight.
-
Glucose Regulation and Insulin Response
GLP-1 and GIP participate in glucose-dependent insulin signaling, while glucagon plays an important role in glucose and energy metabolism. Clinical research is examining how simultaneous activation of all three receptor systems affects blood glucose, insulin, and related metabolic measures.
-
Cardiometabolic Health
Researchers are also studying how triple-receptor agonism affects broader cardiometabolic measures. Clinical trials have reported improvements in measures including blood pressure, glucose, insulin, and several lipid markers, while longer-term cardiovascular outcomes continue to be investigated.
Quick Answer
GLP-3 describes a next-generation approach that acts on GLP-1, GIP, and glucagon receptors. Researchers are studying triple-receptor agonism for its effects on appetite, glucose regulation, energy metabolism, and body weight. Clinical research has demonstrated substantial weight reduction and improvements in several metabolic measures, but this triple-agonist approach remains investigational.
At a Glance
What it is
A next-generation approach combining GLP-1, GIP, and glucagon receptor activity.
Why it attracts attention
Researchers study triple-receptor signaling because the three pathways influence complementary aspects of appetite, glucose regulation, insulin response, and energy metabolism.
What the evidence looks like
Human clinical trials have demonstrated substantial reductions in body weight and improvements in several metabolic measures, while research into the safety and longer-term effects of triple-receptor agonism continues.
Important context
"GLP-3" is being used here to describe a next-generation triple-agonist approach and is not the scientific name of an actual GLP-3 hormone or receptor.
What We Know - and What Remains Unclear
Triple GLP-1/GIP/glucagon receptor agonism has produced substantial effects on body weight in clinical research. Phase 2 research demonstrated significant weight reduction, and more recent Phase 3 trials have reported substantial reductions in body weight and improvements in glycemic measures in studied populations.
That does not mean every claim associated with this approach has been established. The triple-agonist approach remains investigational, and questions about long-term safety, cardiovascular outcomes, durability of effects, and its eventual role in clinical practice continue to be studied.
Anyone considering peptide therapy should have an individualized conversation with a qualified provider who can discuss the current evidence, limitations, health history, medications, laboratory information, and metabolic considerations.
Wellness, Delivered With Care
"Getting IV fluids when I was feeling ill was so beneficial to my healing. I'm grateful for AMIV and the service they provide. I would recommend everyone try this."
Jeff Weaver
Customer
"Very professional. The owners explained this treatment in detail. The procedure I received helped with fatigue and dehydration. I enjoyed the relaxed atmosphere of being in my own home."
Jennifer Belch
Customer
"I have had multiple experiences with Advance Mobile IV and all have been AMAZING! Painless pokes and incredible results, make me feel 100 times better. So thankful I found this company."
Cortlin Beck
Customer
Frequently Asked Questions
Is GLP-3 an actual hormone or receptor?
No. "GLP-3" is an informal term sometimes used to describe triple hormone receptor agonists. It does not refer to an established GLP-3 hormone or receptor.
Which three receptors are involved?
The triple-agonist approach targets GLP-1, GIP, and glucagon receptors. Each participates in different but overlapping aspects of appetite, glucose regulation, insulin response, and energy metabolism.
Why add glucagon receptor activity?
Researchers are investigating whether adding glucagon receptor agonism to GLP-1 and GIP activity may further influence energy intake, substrate utilization, and energy expenditure, potentially contributing to additional metabolic effects.
Has triple-receptor agonism been proven to support weight loss?
Clinical trials have demonstrated substantial weight reduction in studied populations. However, this triple-agonist approach remains investigational and has not yet received FDA approval.
Learn More About Peptide Therapy
Peptide science is complicated, particularly when it involves multiple metabolic and endocrine signaling pathways. Advanced Mobile IV can help you understand the current conversation around GLP-3 and other peptide therapies, the questions to ask, and whether a discussion with a qualified provider makes sense for you.
Call Advanced Mobile IV to Learn MoreThis page is for educational purposes only and is not medical advice. Research and clinical understanding of peptide therapy continue to evolve.
AMIV Wellness Hub
Recent Blog Posts
Mobile IV
Jan 08, 2026
